TY - JOUR
T1 - Fighting Post-COVID and ME/CFS – development of curative therapies
AU - Scheibenbogen, Carmen
AU - Bellmann-Strobl, Judith Theresia
AU - Heindrich, Cornelia
AU - Wittke, Kirsten
AU - Stein, Elisa
AU - Franke, Christiana
AU - Prüss, Harald
AU - Preßler, Hannah
AU - Machule, Marie Luise
AU - Audebert, Heinrich
AU - Finke, Carsten
AU - Zimmermann, Hanna Gwendolyn
AU - Sawitzki, Birgit
AU - Meisel, Christian
AU - Toelle, Markus
AU - Krueger, Anne
AU - Aschenbrenner, Anna C.
AU - Schultze, Joachim L.
AU - Beyer, Marc D.
AU - Ralser, Markus
AU - Mülleder, Michael
AU - Sander, Leif Erik
AU - Konietschke, Frank
AU - Paul, Friedemann
AU - Stojanov, Silvia
AU - Bruckert, Lisa
AU - Hedderich, Dennis M.
AU - Knolle, Franziska
AU - Riemekasten, Gabriela
AU - Vehreschild, Maria J.G.T.
AU - Cornely, Oliver A.
AU - Behrends, Uta
AU - Burock, Susen
N1 - Publisher Copyright:
Copyright © 2023 Scheibenbogen, Bellmann-Strobl, Heindrich, Wittke, Stein, Franke, Prüss, Preßler, Machule, Audebert, Finke, Zimmermann, Sawitzki, Meisel, Toelle, Krueger, Aschenbrenner, Schultze, Beyer, Ralser, Mülleder, Sander, Konietschke, Paul, Stojanov, Bruckert, Hedderich, Knolle, Riemekasten, Vehreschild, Cornely, Behrends and Burock.
PY - 2023
Y1 - 2023
N2 - The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.
AB - The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.
UR - http://www.scopus.com/inward/record.url?scp=85164388992&partnerID=8YFLogxK
U2 - 10.3389/fmed.2023.1194754
DO - 10.3389/fmed.2023.1194754
M3 - Journal articles
AN - SCOPUS:85164388992
SN - 2296-858X
VL - 10
JO - Frontiers in medicine
JF - Frontiers in medicine
M1 - 1194754
ER -
